ASSOCIATION OF OCULAR CATARACTS WITH INHALED AND ORAL STEROID-THERAPY DURING LONG-TERM TREATMENT OF ASTHMA

被引:78
作者
TOOGOOD, JH
MARKOV, AE
BASKERVILLE, J
DYSON, C
机构
[1] UNIV WESTERN ONTARIO,DEPT MED,LONDON N6A 3K7,ONTARIO,CANADA
[2] KIEV INST PHTHISIATRY & PULM,DEPT ALLERGOL,KIEV,UKRAINE
[3] UNIV WESTERN ONTARIO,DEPT STAT & ACTUARIAL SCI STATLAB,LONDON N6A 3K7,ONTARIO,CANADA
[4] UNIV WESTERN ONTARIO,DEPT OPHTHALMOL,LONDON N6A 3K7,ONTARIO,CANADA
[5] VICTORIA HOSP,IVEY INST OPHTHALMOL,LONDON N6A 4G5,ONTARIO,CANADA
关键词
CATARACTS; STEROID COMPLICATIONS; GLUCOCORTICOIDS; INHALED STEROIDS; BUDESONIDE; BECLOMETHASONE; DEXAMETHASONE;
D O I
10.1016/0091-6749(93)90263-F
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Posterior subcapsular cataracts (PSCs) have been reported to occur in some asthmatic patients treated with inhaled steroids. Methods: We studied the associations between the occurrence of PSCs and inhaled and oral steroid therapy in 48 adults in a cross-sectional survey by slit lamp. Accurate records of the patients' long-term usage of these drugs were available: 9.2 +/- 5.2 years for inhaled steroid and 9.1 +/- 9.3 years for prednisone (mean +/- SD). Their current inhaled steroid dosage averaged 1.46 +/- 0.85 mg/day (range, 0 to 3.2 mg/day). Results: Twenty-seven percent of the group had PSCs. The occurrence of PSCs correlated with the current daily dose and duration of prednisone use (p = 0.002 and p = 0.01, respectively), but not with the dose or duration of inhaled steroid treatment. As judged by multiple logistic regression analysis, neither the particular inhaled steroid drug used, nor its daily dose or cumulative dose, nor the additional nonsteroidal risk factors for PSCs also present in some of these patients contributed significantly to their risk of developing PSCs. Conclusions: The findings do not exclude the possibility that inhaled steroid therapy might lead to PSCs if a person has an exceptionally high inherent susceptibility. However, in the asthmatic population at large, the risk appears negligible, even if high doses of inhaled steroid are administered.
引用
收藏
页码:571 / 579
页数:9
相关论文
共 61 条
[41]  
Spaeth G L, 1966, Int Ophthalmol Clin, V6, P915, DOI 10.1097/00004397-196606040-00009
[42]   INHALED CORTICOSTEROIDS, BONE-FORMATION, AND OSTEOCALCIN [J].
TEELUCKSINGH, S ;
PADFIELD, PL ;
TIBI, L ;
GOUGH, KJ ;
HOLT, PR .
LANCET, 1991, 338 (8758) :60-61
[43]   BIOEQUIVALENT DOSES OF BUDESONIDE AND PREDNISONE IN MODERATE AND SEVERE ASTHMA [J].
TOOGOOD, JH ;
BASKERVILLE, J ;
JENNINGS, B ;
LEFCOE, NM ;
JOHANSSON, SA .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1989, 84 (05) :688-700
[44]  
TOOGOOD JH, 1990, AM REV RESPIR DIS, V141, pS89
[45]   USE OF SPACERS TO FACILITATE INHALED CORTICOSTEROID TREATMENT OF ASTHMA [J].
TOOGOOD, JH ;
BASKERVILLE, J ;
JENNINGS, B ;
LEFCOE, NM ;
JOHANSSON, SA .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1984, 129 (05) :723-729
[46]   EFFECTS OF DOSE AND DOSING SCHEDULE OF INHALED BUDESONIDE ON BONE TURNOVER [J].
TOOGOOD, JH ;
JENNINGS, B ;
HODSMAN, AB ;
BASKERVILLE, J ;
FRAHER, LJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1991, 88 (04) :572-580
[47]  
TOOGOOD JH, 1991, ANN ALLERGY, V67, P87
[48]  
TOOGOOD JH, 1992, J ALLERGY CLIN IMMUN, V89, P186
[49]   MINIMUM DOSE REQUIREMENTS OF STEROID-DEPENDENT ASTHMATIC-PATIENTS FOR AEROSOL BECLOMETHASONE AND ORAL PREDNISONE [J].
TOOGOOD, JH ;
LEFCOE, NM ;
HAINES, DSM ;
CHUANG, L ;
JENNINGS, B ;
ERRINGTON, N ;
BAKSH, L ;
CAUCHI, M .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1978, 61 (06) :355-364
[50]  
TOOGOOD JH, 1991, TODAYS THERAPEUTIC T, V9, P9